Latest Healthcare News

OncoSil Medical’s interim OSPREY Registry data show strong safety and promising survival outcomes for its targeted radiotherapy device in unresectable locally advanced pancreatic cancer, surpassing historical benchmarks.

AVITA Medical reported a 4% revenue increase in Q1 2026 with a narrowed net loss, underpinned by a new BARDA contract and promising Cohealyx clinical data. Leadership changes and regulatory approvals support a confident outlook.

Pacific Edge edges closer to a Medicare breakthrough with a draft Local Coverage Determination proposing coverage for its Cxbladder Triage and Triage Plus tests, potentially unlocking reimbursement for over 66 million US patients.

Lumos Diagnostics has reached a key enrolment milestone in its BARDA-backed FebriDx paediatric trial, unlocking a US$670,000 payment and advancing its FDA submission pathway to expand use in children aged 2-12 years.

Despite sweeping changes to Capital Gains Tax announced in the 2026/27 Federal Budget, Acrux Limited’s status as a Pooled Development Fund ensures its shareholders remain shielded from these new tax rules.

Nexsen has secured a strategic partnership with GHK Hospital Limited in Hong Kong, marking a significant step in validating and commercialising its rapid point-of-care diagnostics across North Asia.

Healius updates FY26 guidance with modest earnings growth, flags wage cost pressures from Fair Work ruling, and initiates sale process for high-growth Agilex Biolabs.

Marlin Global delivered a 4.0% gross portfolio return in April 2026, driven by strong gains in AI-focused tech stocks like Amazon and Alphabet. However, its cautious stance on semiconductors limited upside amid a sector rally.

Barramundi Limited outperformed the S&P/ASX200 in April with a 4.4% gross return, boosted by NEXT DC’s landmark data centre deal and capital raise, while healthcare stocks faced headwinds from Cochlear’s profit downgrade.

Kingfish Limited’s portfolio edged higher in April, buoyed by strong performances from Mercury and Infratil, while a2 Milk and Summerset weighed on returns amid operational and economic headwinds.

EBR Systems accelerated its U.S. commercial rollout of the WiSE CRT System in Q1 2026 with implant volumes more than doubling and revenue hitting US$2.4 million. The company also secured a key regulatory milestone in Australia with TGA Priority Review, yet losses deepened and cash burn intensified, raising fresh questions about its funding runway.

Enlitic’s Ensight platform goes live at New Zealand’s largest private radiology provider, marking a milestone in its Intelerad partnership and expanding its global footprint after record contract wins.